Postdoctoral Fellows

Name:
Matthias D’Huyvetter

Degree:
Master in Biomedical Sciences
PhD in Medical Sciences
Professor

PhD Thesis:
Title: Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
Author: Matthias D’huyvetter
Promotion Year: 2014
Promotor: Tony Lahoutte, Vicky Caveliers & Nick Devoogdt
Co-promotor: Michael Zalutsky & An Aerts
Flyer

Affiliation:
In vivo Cellular and Molecular Imaging Laboratory (ICMI)

Research Focus:
Targeted Radionuclide Therapy

Contributions to science:
The ICMI lab has focused on using sdAbs as tools for molecular imaging. I was involved in the preclinical development.
  • Xavier C., Blykers A., Vaneycken I., D’Huyvetter M., Heemskerk J., Lahoutte T., Devoogdt N., Caveliers V. 18F-Nanobody for PET imaging of HER2 overexpressing tumors. Nucl Med Biol 2016;43:247-252.
    • Blykers A., Schoonooghe S., Xavier C., D'hoe K., Laoui D., D'Huyvetter M., Vaneycken I., Cleeren F., Bormans G., Heemskerk J., Raes G., De Baetselier P., Lahoutte T., Devoogdt N., Van Ginderachter JA., Caveliers V. PET imaging of MMR-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J Nucl Med. 2015;56(8):1265-71.
    • Xavier C., Vaneycken I., D'huyvetter M., Heemskerk J., Keyaerts M., Vincke C., Devoogdt N., Muyldermans S., Lahoutte T., Caveliers V. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54(5):776-84.
    • Vaneycken I., D'huyvetter M., Hernot S., De Vos J., Xavier C.,Devoogdt N., Caveliers V., Lahoutte T. Immuno-imaging using nanobodies. Curr Opin Biotechnol. 2011;22(6):877-81.

More recently we endeavored the use of sdAbs as vehicles for targeted radionuclide therapy. This is now my dominant research focus.
  • Dekempeneer Y., Keyaerts M., Krasniqi A., Puttemans J., Muyldermans S., Lahoutte T., D'Huyvetter M*., Devoogdt N*. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther. 2016 May 19:1-13. Authors contributed equally.
    • D'Huyvetter M., Vincke C., Xavier C., Aerts A., Impens N., Baatout S., De Raeve H., Muyldermans S., Caveliers V., Devoogdt N., Lahoutte T. Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody. Theranostics. 2014;25;4(7):708-20.
    • Lemaire M., D'Huyvetter M., Lahoutte T., Van Valckenborgh E., Menu E., De Bruyne E., Kronenberger P., Wernery U., Muyldermans S., Devoogdt N., Vanderkerken K. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Leukemia. 2014;28(2):444-7.
    • D'Huyvetter M., Aerts A., Xavier C., Vaneycken I., Devoogdt N., Gijs M., Impens N., Baatout S., Ponsard B., Muyldermans S., Caveliers V., Lahoutte T. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging. 2012;7(2):254-64.

Complete List of Published Work:
https://www.ncbi.nlm.nih.gov/pubmed/?term=D'Huyvetter+M

Address:
Vrije Universiteit Brussel
Department BEFY, Labo ICMI, Building K
Laarbeeklaan 103
1090 Jette (Brussels)
Belgium

Telephone:
0032 (0)2 477 49 91

Email:
mdhuyvet@vub.ac.be